Overview
Topics Covered in This Report Include the Following:
- The pros and cons of protein arrays versus traditional DNA microarrays.
- How some groups are dealing with complications such as alternative splicing.
- The advancement of microarrays from pure research applications toward the clinic.
- New tools and approaches for microarray analysis.
The DNA microarray marketplace is changing rapidly. Microarrays are already widely adopted, and many use2rs are now going beyond exploratory studies. With a better understanding of what is required to get optimal results from this potentially finicky technology platform, researchers are getting more robust data from their studies, and findings with potential clinical applicability are trickling in. At the same time, several major developments are making it increasingly challenging to maintain viable business models in this arena.
Many experts believe that DNA microarrays will be used for some years to come, despite increasing competition from protein arrays. Perhaps the most promising commercial application of microarrays is their potential use as clinical diagnostics; this area will likely attract more and more players over time if this approach continues to show promise. Intriguing results are beginning to emerge from the use of DNA microarrays to classify subtypes of cancer and to guide treatment decisions. If they could be optimized further for clinical applications in classifying disease, to determine the most appropriate treatments, their market potential could be significant.
This report provides an overview of the scientific basis of microarrays, explains how to optimize results obtained from these tools, details the competitors in this market and the distinctions among their products, and analyzes and forecasts the market dynamics. The activities of approximately 100 companies are reviewed, 15 companies are profiled (with financial capsules), and 16 expert commentaries or interviews are presented. Dealmaking trends in microarrays are also discussed, based on data from CHIfs Drug Discovery and Development Deals Database.
Editorial Advisory Board: Stanley Abramowitz, ATG Advanced Technology Group; Alon Amit, Compugen; Timothy Connolly, Aventis Genomics Center; David Dorris, Motorola Life Sciences; David Finkelstein, Affymetrix; Donald J. Kessler, Agilent Technologies; Ulrik B. Nielsen, Merrimack Pharmaceuticals; Douglas Ross, Applied Genomics; Alan Roter, Iconix Pharmaceuticals; Winston K. Wong, Stratagene; Ali Zareh, Corimbia
Other Experts Interviewed: Gene Brown, Genetics Institute/Wyeth-Ayerst Research; Tom Downey, Partek; Sam Hicken, Phase-1 Molecular Toxicology; Eric Neumann, Beyond Genomics; N. Stephen Ober, Beyond Genomics
View Cart
